Barinthus Biotherapeutics Plc ADR (BRNS) Stock Price, Quote & News

Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent hig...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 1865 818 808

Website: www.barinthusbio.com

Address:

Zeus Building, Unit 6-10 Rutherford Avenue Harwell, Didcot, United Kingdom

elmono Nov. 18 at 10:49 PM

$BRNS going sub 40 cts soon…..

0 · Reply

Alorenz94 Nov. 18 at 7:41 AM

$BRNS 4 possible scenarios for the VTP-1000 readout. Asked chat to do a probability weighted expected price on: A) strong positive data B) positive but not mind blowing data C) mixed data/inconclusive D) bad/negative Used the price range midpoint for each scenario. Outcome is as follow - $1.91/ share. This excludes merger price action, CLY’s pipeline, and the mentioned stock buyback so upside is likely way higher than $1.91/share.

1 · Reply

Alorenz94 Nov. 18 at 2:33 AM

$BRNS …..As of the recent Q325 earnings PR, PH 1 SAD is “ongoing with no treatment related serious adverse events reported” (positive indicator for the drug’s safety profile). And 4 clinical data milestones expected within 18mo of the closing of the transaction in 1H 2026. Need closing to be early Q1 lol. Bleeding ATM. H.C. wainwright analyst Yi Chen reiterated his BUY rating on BRNS today and set a PT Of $4/ share today as well for what it’s worth

0 · Reply

Alorenz94 Nov. 18 at 2:17 AM

$BRNS cash runway of combined company extends through 2027. Transaction expected to close 1H26. Ph 1 SAD data expected Q425: —single ascending dose data readout for VTP-1000 expected before year end. PH 1 MAD data expected 2H26 —enrollment advancing in multiple ascending dose part of AVALON trial, data expected 2H26 Other milestones expected in H1/H2 2026. VTP-850,200,600,500 unclear what will be of these post merger. Looks like the focus is BRNS’ VTP-1000 and Clyewedog’s-101 and 201 inhibitors for Type 1/2 Diabetes.

1 · Reply

Alorenz94 Nov. 17 at 9:15 PM

$BRNS large Block end of day

0 · Reply

DARKP00L Nov. 17 at 12:39 PM

$BRNS 07:29 on Nov. 17 2025 HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4 #tradeideas

0 · Reply

JarvisFlow Nov. 17 at 12:29 PM

HC Wainwright & Co. updates rating for Barinthus Biotherapeutics ( $BRNS ) to Buy, target set at 3 → 4.

0 · Reply

skyrockets_Inc Nov. 11 at 6:37 PM

$BRNS why such a harsh drop?

1 · Reply

elmono Nov. 10 at 5:04 PM

$BRNS and another nano crap outfit announcing a data delay….starting to become a habit with all these bio zombies 😂😂😂😂

0 · Reply

CometaMan Nov. 10 at 4:51 PM

$BRNS wow! What a drop. Good potential now?

0 · Reply

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

Oct 3, 2025, 1:23 PM EDT - 6 weeks ago

BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

Sep 30, 2025, 9:56 AM EDT - 7 weeks ago

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

Jun 9, 2025, 9:00 AM EDT - 5 months ago

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

Mar 20, 2025, 7:22 AM EDT - 8 months ago

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Mar 6, 2025, 8:30 AM EST - 9 months ago

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

Jan 10, 2025, 8:00 AM EST - 11 months ago

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Nov 25, 2024, 4:01 PM EST - 1 year ago

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Nov 15, 2024, 11:02 AM EST - 1 year ago

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Nov 15, 2024, 11:01 AM EST - 1 year ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Nov 6, 2024, 8:00 AM EST - 1 year ago

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

May 13, 2024, 8:00 AM EDT - 1 year ago

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

May 1, 2024, 7:00 AM EDT - 1 year ago

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Apr 18, 2024, 4:10 PM EDT - 1 year ago

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Jan 5, 2024, 4:01 PM EST - 2 years ago

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Dec 21, 2023, 7:31 AM EST - 2 years ago

New partnership aims to advance vaccine against MERS coronavirus

Nov 9, 2023, 4:24 PM EST - 2 years ago

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Nov 9, 2023, 4:01 PM EST - 2 years ago

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Nov 6, 2023, 9:05 AM EST - 2 years ago

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Sep 13, 2023, 8:00 AM EDT - 2 years ago

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Jun 21, 2023, 9:03 AM EDT - 2 years ago

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Jun 12, 2023, 7:30 AM EDT - 2 years ago

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

May 12, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Mar 24, 2023, 8:06 AM EDT - 2 years ago

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Nov 21, 2022, 10:31 AM EST - 3 years ago

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Nov 10, 2022, 4:30 PM EST - 3 years ago

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Nov 7, 2022, 8:00 AM EST - 3 years ago

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Nov 2, 2022, 8:00 AM EDT - 3 years ago

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Sep 20, 2022, 4:30 PM EDT - 3 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 7, 2022, 4:01 PM EDT - 3 years ago

Vaccitech to Present at Upcoming September Investors Conferences

Aug 9, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Jul 7, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Jun 22, 2022, 1:48 PM EDT - 3 years ago

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Jun 22, 2022, 6:00 AM EDT - 3 years ago

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Jun 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 7:32 AM EDT - 3 years ago

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

May 20, 2022, 11:30 AM EDT - 3 years ago

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

May 11, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Apr 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Apr 3, 2022, 7:57 PM EDT - 3 years ago

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Mar 25, 2022, 7:15 AM EDT - 3 years ago

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Mar 7, 2022, 8:00 AM EST - 4 years ago

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Jan 18, 2022, 3:00 AM EST - 4 years ago

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

elmono Nov. 18 at 10:49 PM

$BRNS going sub 40 cts soon…..

0 · Reply

Alorenz94 Nov. 18 at 7:41 AM

1 · Reply

Alorenz94 Nov. 18 at 2:33 AM

0 · Reply

Alorenz94 Nov. 18 at 2:17 AM

1 · Reply

Alorenz94 Nov. 17 at 9:15 PM

$BRNS large Block end of day

0 · Reply

DARKP00L Nov. 17 at 12:39 PM

$BRNS 07:29 on Nov. 17 2025 HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4 #tradeideas

0 · Reply

JarvisFlow Nov. 17 at 12:29 PM

HC Wainwright & Co. updates rating for Barinthus Biotherapeutics ( $BRNS ) to Buy, target set at 3 → 4.

0 · Reply

skyrockets_Inc Nov. 11 at 6:37 PM

$BRNS why such a harsh drop?

1 · Reply

elmono Nov. 10 at 5:04 PM

$BRNS and another nano crap outfit announcing a data delay….starting to become a habit with all these bio zombies 😂😂😂😂

0 · Reply

CometaMan Nov. 10 at 4:51 PM

$BRNS wow! What a drop. Good potential now?

0 · Reply

Alorenz94 Nov. 10 at 4:43 PM

$BRNS down 30%???

0 · Reply

DocPharm Nov. 7 at 4:58 PM

$BRNS there’s the gap fill at 1.05 Now time for some indecision

0 · Reply

johnnygogogo Nov. 3 at 8:44 PM

$BRNS where is the VTP-1000 data?

0 · Reply

Alorenz94 Oct. 27 at 8:24 PM

$BRNS @skyrockets_Inc did you trim any more? Im probably holding for 1 more week then trimming

1 · Reply

DocPharm Oct. 24 at 4:57 PM

$BRNS wonder what they are doing with VTP-300

0 · Reply

DARKP00L Oct. 24 at 3:08 PM

$BRNS 11:05 on Oct. 24 2025 ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq #tradeideas

0 · Reply

HattysRevenge Oct. 23 at 4:35 PM

$BRNS Billy boys favorite tool ! It's mind blowing ! Is Clywedog a New Jersey Company ? 😁

0 · Reply

Alorenz94 Oct. 22 at 6:41 PM

$BRNS $2+ End of Year

1 · Reply

johnnygogogo Oct. 22 at 3:26 PM

$BRNS “with the SAD data readout expected early in the fourth quarter of 2025” - today is Oct. 22. Tick tock. November is no longer “early” imo.

0 · Reply

Alorenz94 Oct. 19 at 1:21 PM

$BRNS Because Barinthus is in a merger process: • A buyback might be delayed until after the merger closes (or until the boards of the combining entities approve it). • Executing a significant share repurchase pre-closing could complicate the deal structure (e.g., ownership percentages, cash position). • If the CEO has referenced a buyback “sooner rather than later,” “sooner” might still mean after the merger or at least after key approvals.

0 · Reply

johnnygogogo Oct. 17 at 4:18 PM

$BRNS VTP-1000 data release has to be soon but I don’t see the S-3 filed yet for the buyback. cc: @skyrockets_Inc

1 · Reply

DocPharm Oct. 17 at 2:27 PM

$BRNS almost adding time again

0 · Reply

Market Cap	31.41M
Revenue (ttm)	14.97M
Net Income (ttm)	-61.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-407.95%
Debt to Equity Ratio	0.00

Volume	153,900
Avg Vol	169,610
Day's Range	N/A - N/A
Shares Out	40.83M
Stochastic %K	7%
Beta	-0.70
Analysts	Strong Sell
Price Target	$5.67